Espansione Group Announces Dry AMD Multi-center Trial Kick-off

Hanson Instruments

Bologna (Italy)—October 6th 2022

Espansione Group, the leading medical device company offering screening and treatment solutions for ocular conditions, announced today the kick-off of a multi-center clinical trial focused on non-neovascular (dry) Age-Related Macular Degeneration (AMD) through its patented technology Light Modulation® Low-level Light Therapy (LM® LLLT), a medical-grade photobiomodulation (PBM) technology globally certified already in over 50 countries.

Recruitment for the study has already started. The research will involve a total of 350 patients affected by dry AMD: of these 175 patients will receive a new LM® LLLT protocol specifically developed for AMD by Espansione Group's scientific committee, while the remaining 175 patients will act as control group. This body of work will leverage LM® LLLT, administered via eye-light® solution, in a partnership with 7 leading retinal diseases centers across the European continent and even more top-tier exponents of the scientific community:

  • Prof. G. Giannaccare, Prof. V. Scorcia—University of Catanzaro (ITA)
  • Prof. A Vagge, Prof. M. Nicolò—University of Genoa (ITA)
  • Dr. C. Iovino, Prof. F. Simonelli—University of Naples (ITA)
  • Dr. M. Pellegrini, Prof. M. Busin—University of Ferrara (ITA)
  • Dr. P.R. Rothschild, Dr. Federico Bernabei—University of Paris (FRA)
  • Dr. S. Farrant (TFOS Ambassador)—Earlam and Christopher, Taunton (GBR)
  • Dr. Neşe Erten—Uncali Meydan Clinic (TUR)

The main visual and anatomical outcomes of the study will include changes of visual acuity, number and size of drusen, contrast sensitivity, as well as overall quality of life of patients involved.


Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The dry AMD subtype accounts for 85-90% of cases, with a global prevalence of 0.44%, increasing with age. Over 280 million people will be affected by 2040. With a global prevalence amongst the elderly, dry AMD is a multifactorial disease: age, genetics, race (most common for caucasians), smoking, obesity and cardiovascular diseases are the main factors playing a role in augmenting the risk of dry AMD arising.



Espansione Group is an established player in the MedTech industry focusing on ophthalmic and dermatological solutions to treat a number of conditions via patented, certified, light-based technologies such as Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL).

Since 1981, Espansione Group has delivered the highest standard in the industry—pushed on by expert craftsmanship and family-owned values coupled with a global mindset and aspiration. Every day, the company invests heavily in researching and developing the Espansione Ecosystem of technologies and solutions to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by the desire to provide its partners and their patients with the best, certified medical technologies.

With more than 6 international patents and over 1,100 solutions installed worldwide, Espansione Group's technologies are responsible for the betterment of thousands of people worldwide, with over 400,000 yearly treatments being carried out each year with its solutions.

The scientific community has already crowned the efficacy of Espansione Group's technology: dozens of global KOLs in the fields of ophthalmology and dermatology endorse the company's LM® LLLT technology for its simplicity and efficacy. Over 25 scientific publications and counting have been released since 2018, with over 2,000 patients involved to date in field research studies.

Present in over 50 countires, Espansione Group's is bound to hold strong on its strong growth path in the years to come, relentlessly focusing its efforts on research, development and customer excellence.